Clinical Roundup Sugemalimab is a potential treatment option in a broad range of NSCLC patients, stage 3 and 4 studies suggest September 24, 2021Vol.47 No.35
Clinical Roundup Libtayo + chemo significantly improve OS in advanced NSCLC September 24, 2021Vol.47 No.35
Clinical Roundup HER2-targeting antibody-drug improves PFS in deadly form of advanced breast cancer September 24, 2021Vol.47 No.35
Clinical Roundup Keytruda + chemo reduces risk of death by one-third vs. chemo as first-line treatment for persistent, recurrent, or metastatic cervical cancer September 24, 2021Vol.47 No.35
Clinical Roundup Tecentriq shows promise in treating early-stage lung cancer September 24, 2021Vol.47 No.35
Clinical Roundup MIT study finds global cancer risk from burning organic matter comes from unregulated chemicals September 24, 2021Vol.47 No.35
Clinical Roundup Four out of five cancer therapies tested in phase III trials do not achieve clinically-meaningful benefit in prolonging survival September 24, 2021Vol.47 No.35
Clinical Roundup Phase III GEMSTONE-302 study demonstrates clinical benefit of sugemalimab plus chemotherapy in treating NSCLC September 17, 2021Vol.47 No.34
Clinical Roundup Cabometyx in combination with Opdivo provides efficacy benefits regardless of prior nephrectomy in patients with previously untreated advanced RCC September 17, 2021Vol.47 No.34
Clinical Roundup LLS says third COVID-19 shot can boost antibody levels in blood cancer patients September 17, 2021Vol.47 No.34
